Table 1. Baseline demographics of the patients.
| Variables | Overall | LVI status |
||
|---|---|---|---|---|
| LVI (+) | LVI (−) | p-value | ||
| Age (years)* | 66.2, 67.0 (±6.5) | 66.4, 67.0 (±6.1) | 66.1, 66.5 (±6.6) | 0.603 |
| BMI (kg/m2)* | 24.6, 24.6 (±2.8) | 24.4, 24.2 (±2.8) | 24.7, 24.8 (±2.8) | 0.213 |
| Preoperative PSA (ng/mL)* | 15.7, 10.9 (±17.7) | 23.0, 14.8 (±28.0) | 13.6, 9.9 (±12.9) | <0.001 |
| Total biopsy cores (n)* | 11.3, 12.0 (±1.9) | 11.5, 12.0 (±1.9) | 11.2, 12.0 (±1.9) | 0.088 |
| Positive cores (n)* | 4.9, 4.0 (±2.9) | 5.6, 6.0 (±3.2) | 4.4, 4.0 (±2.8) | <0.001 |
| Biopsy Gleason score (%) | <0.001 | |||
| ≤6 | 307 (25.4) | 33 (12.8) | 274 (29.1) | |
| 7 (3+4) | 321 (26.5) | 55 (21.4) | 266 (28.2) | |
| 7 (4+3) | 197 (16.3) | 43 (16.7) | 154 (16.3) | |
| ≥8 | 374 (30.9) | 126 (49.0) | 248 (26.3) | |
| Prostate volume (mL)* | 35.5, 33.0 (±13.9) | 37.2, 36.0 (± 14.5) | 35.0, 32.4 (±13.6) | 0.025 |
| Tumor volume (%) | 0.001 | |||
| ≤5 mL | 568 (46.9) | 101 (41.1) | 467 (53.3) | |
| >5 mL | 554 (45.8) | 145 (58.9) | 409 (46.7) | |
| Extracapsular extension (%) | 1179 (97.4) | 251 (96.5) | 928 (97.8) | 0.251 |
| Seminal vesicle invasion (%) | 297 (24.5) | 118 (45.4) | 178 (18.8) | <0.001 |
| Positive surgical margin (%) | 716 (59.2) | 171 (65.8) | 544 (57.3) | 0.014 |
| Perineural invasion (%) | 1103 (91.2) | 250 (96.2) | 853 (89.9) | 0.002 |
| Pathologic Gleason score (%) | <0.001 | |||
| ≤6 | 85 (7.0) | 4 (1.5) | 81 (8.6) | |
| 7 (3+4) | 452 (37.4) | 52 (20.1) | 400 (42.2) | |
| 7 (4+3) | 350 (28.9) | 95 (36.7) | 255 (26.9) | |
| ≥8 | 320 (26.4) | 108 (41.7) | 211 (22.3) | |
*Values are expressed as mean, median (±SD)
LVI, lymphovascular invasion; BMI, body mass index; PSA, prostate-specific antigen.